Terbinafine inhibits oral squamous cell carcinoma growth through anti-cancer cell proliferation and anti-angiogenesis

Molecular Carcinogenesis

Volumn 51, Issue 5, 2012, Pages 389-399

  Chien, Ming Hsien ^a,b   Lee, Tong Sheng ^c,d   Kao, Chieh ^c   Yang, Shun Fa ^e   Lee, Wen Sen ^c,f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cell cycle arrest; Oral squamous cell carcinoma; P21 cip; P27 kip; Terbinafine

Indexed keywords

CELL NUCLEUS ANTIGEN; PROTEIN P21; PROTEIN P27; TERBINAFINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL PROLIFERATION; CYTOTOXICITY; DNA SYNTHESIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROVASCULATURE; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOUTH NEOPLASMS; NAPHTHALENES; NEOVASCULARIZATION, PATHOLOGIC; NUCLEIC ACID SYNTHESIS INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84859764043     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20800     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: Factors affecting survival. J Oral Maxillofac Surg 2003; 61: 751-758.
3. Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: New class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239-1241.
4. Abdel-Rahman SM, Nahata MC. Oral terbinafine: A new antifungal agent. Ann Pharmacother 1997; 31: 445-456.
5. Gupta AK, Shear NH. Terbinafine: An update. J Am Acad Dermatol 1997; 37: 979-988.
6. Gupta AK, del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: Three case reports and a review of the literature. Clin Exp Dermatol 1998; 23: 64-67.
7. Lee WS, Chen RJ, Wang YJ, et al. In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/g1 p53-associated cell cycle arrest. Int J Cancer 2003; 106: 125-137.
8. Ho PY, Liang YC, Ho YS, Chen CT, Lee WS. Inhibition of human vascular endothelial cells proliferation by terbinafine. Int J Cancer 2004; 111: 51-59.
9. Jain M, He Q, Lee WS, et al. Role of cd44 in the reaction of vascular smooth muscle cells to arterial wall injury. J Clin Invest 1996; 97: 596-603.
10. Lin SY, Liu JD, Chang HC, Yeh SD, Lin CH, Lee WS. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. J Cell Biochem 2002; 84: 532-544.
11. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing mcl-1-dependent survival mechanism in human lung adenocarcinoma cl1.0 cells. Involvement of phosphatidylinositol 3-kinase/akt pathway. J Biol Chem 2001; 276: 48997-49002.
12. Lin SY, Liang YC, Ho YS, Tsai SH, Pan S, Lee WS. Involvement of both extracellular signal-regulated kinase and c-jun n-terminal kinase pathways in the 12-o-tetradecanoylphorbol-13-acetate-induced upregulation of p21(cip1) in colon cancer cells. Mol Carcinog 2002; 35: 21-28.
13. Lin SY, Chang YT, Liu JD, et al. Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells. Mol Carcinog 2001; 32: 73-83.
14. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against kb carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988; 80: 1605-1611.
15. Cursiefen C, Schlotzer-Schrehardt U, Kuchle M, et al. Lymphatic vessels in vascularized human corneas: Immunohistochemical investigation using lyve-1 and podoplanin. Invest Ophthalmol Vis Sci 2002; 43: 2127-2135.
16. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
17. Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci USA 1997; 94: 2776-2778.
18. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature 1996; 381: 643-644.
19. Macleod KF, Sherry N, Hannon G, et al. P53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935-944.
20. Braun-Dullaeus RC, Mann MJ, Sedding DG, Sherwood SW, von der Leyen HE, Dzau VJ. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol 2004; 24: 845-850.
21. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 2002; 8: 1249-1256.
22. Sherr CJ, Roberts JM. Cdk inhibitors: Positive and negative regulators of g1-phase progression. Genes Dev 1999; 13: 1501-1512.
23. Ortega S, Malumbres M, Barbacid M. Cyclin d-dependent kinases, ink4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602: 73-87.
24. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: A function for each cell compartment? Trends Cell Biol 2003; 13: 65-70.
25. Baral R, Patnaik S, Das BR. Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. Eur J Oral Sci 1998; 106: 907-913.
26. Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477-4480.
27. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ. P53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 1993; 142: 1131-1139.
28. Chen YJ, Jin YT, Shieh DB, Tsai ST, Wu LW. Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells. Oral Oncol 2002; 38: 699-705.
29. Min BM, Baek JH, Shin KH, Gujuluva CN, Cherrick HM, Park NH. Inactivation of the p53 gene by either mutation or hpv infection is extremely frequent in human oral squamous cell carcinoma cell lines. Eur J Cancer B Oral Oncol 1994; 30B: 338-345.
30. Mirjolet JF, Barberi-Heyob M, Didelot C, et al. Bcl-2/bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 2000; 83: 1380-1386.
31. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
32. Alcalde RE, Shintani S, Yoshihama Y, Matsumura T. Cell proliferation and tumor angiogenesis in oral squamous cell carcinoma. Anticancer Res 1995; 15: 1417-1422.
33. Macluskey M, Chandrachud LM, Pazouki S, et al. Apoptosis, proliferation, and angiogenesis in oral tissues. Possible relevance to tumour progression. J Pathol 2000; 191: 368-375.
34. Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S, Jurkiewicz MJ. Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg 1994; 168: 373-380.
35. Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H. Expression of vascular endothelial growth factor a, b, c, and d in oral squamous cell carcinoma. Oral Oncol 2004; 40: 13-20.
36. Okada Y, Ueno H, Katagiri M, et al. Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology 2010; 98: 52-59.
37. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998; 58: 2288-2292.
38. Ho PY, Hsu SP, Liang YC, Kuo ML, Ho YS, Lee WS. Inhibition of the erk phosphorylation plays a role in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells. Toxicol Appl Pharmacol 2008; 229: 86-93.
39. Hsu SP, Ho PY, Liang YC, Ho YS, Lee WS. Involvement of the jnk activation in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells. J Cell Biochem 2009; 108: 860-866.
40. Jensen JC. Clinical pharmacokinetics of terbinafine (lamisil). Clin Exp Dermatol 1989; 14: 110-113.
41. Humbert H, Cabiac MD, Denouel J, Kirkesseli S. Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm Drug Dispos 1995; 16: 685-694.
42. Kovarik JM, Mueller EA, Zehender H, Denouel J, Caplain H, Millerioux L. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995; 39: 2738-2741.
43. Faergemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol 1991; 71: 322-326.
44. Schatz F, Brautigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-383.
45. Klobucnikova V, Kohut P, Leber R, et al. Terbinafine resistance in a pleiotropic yeast mutant is caused by a single point mutation in the erg1 gene. Biochem Biophys Res Commun 2003; 309: 666-671.
46. Juhlin L. Loss of taste and terbinafine. Lancet 1992; 339: 1483.
47. Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: Analysis of the elderly subgroup in improving results in onychomycosis-concomitant lamisil and debridement (iron-clad), an open-label, randomized trial. Am J Geriatr Pharmacother 2006; 4: 1-13.